HERIDATARY

SMN1M-RT50/SMN1M-RT500

SMN1 Exon 7/8 Deletion Screening Kit



Technical Specifications

Intended Use

- SMA is an autosomal recessive disease caused by a mutation on SMN1 (Survival Motor Neuron) gene. 94% of SMA are caused by either deletion or duplication on exon 7 and exon 8 of SMN1 gene and it can be detected by widely used molecular analysis. The purpose of this kit is to determine if the patient has the mutations and weather if it is present in their both chromosomes (SMA patient) or on single chromosome (SMA carrier).

Suitable Sample Type

-Whole Blood in tube with EDTA

Test Procedure

-DNA Isolation

-Multiplex RT-qPCR

Validated PCR Instruments

- Bio-Rad CFX96
- Life Technologies ABI-7500
- BioMolecular Systems, MicPCR
- QuantStudio™ 5 Real-Time PCR System

Catalog Number

-SMN1M-RT50/SMN1M-RT500

Contact

Halil Rıfat Paşa Mah. Güler St. GNM PLAZA No:51/1Sisli-Istanbul 34384 TÜRKİYE
Tel: +90-(212)288 74 92-93
Fax: +90-(212)288 74 53
Web: www.genmark.com.tr
E-mail: info@genmark.com.tr

Wildtype



Homozygot



- ✓ This kit uses Real-time PCR based method.
- ✓ The determination of heterozygote, homozygote and wild type could be done with primer-probe.
- ✓ The test system is designed with unique primers specific to sequence.

GeneMAP™ SMN1 Exon 7/8 Deletion Screening Kit is designed specifically for mutation secreening with routine RT-qPCR. It is easy to use, cost efficient and compatible with many Real-time PCR instruments.

Reagents	Vol. per Tube (µl) (RT50 / RT500)
2X Master Mix with UDG	550 µl / 1100 µl
4XMutation Primer Probe Mix	250 µl / 500 µl
Wildtype Control	50 µl

Genmark Sağlık Ürünleri İTH. İHR SAN. TİC. LTD.

In **GENMARK SAGLIK URUNLERI,** we aim to create the top quality, time and cost efficient, trust-worthy and user-friendly products. We specialize in in-vitro detection kit production and development which is used for the **diagnosis** and **treatment monitoring** of many diseases connected to genetics, oncology, microbiology and hematological oncology.